tar*-mediated restoration of EB ganglia requires endoderm-derived Fgf3*
| . | n† . | f . | g . | Small v . | Large v . |
|---|---|---|---|---|---|
| Transplant of GFP-positive wt cells into cas-MO | 15 | 0‡ | 0 | 0 | n/d |
| Transplant of tar* cells into cas-MO | 45 | 21‡ (47%) | 7 (16%) | 10 (22%) | n/d |
| Transplant of tar*+fgf3-MO1 cells into cas-MO§ | 30 | 2‡ (7%) | 2 (7%) | 2 (7%) | n/d |
| . | n† . | f . | g . | Small v . | Large v . |
|---|---|---|---|---|---|
| Transplant of GFP-positive wt cells into cas-MO | 15 | 0‡ | 0 | 0 | n/d |
| Transplant of tar* cells into cas-MO | 45 | 21‡ (47%) | 7 (16%) | 10 (22%) | n/d |
| Transplant of tar*+fgf3-MO1 cells into cas-MO§ | 30 | 2‡ (7%) | 2 (7%) | 2 (7%) | n/d |
wt, wild type; f, facial ganglion; g, glossopharyngeal ganglion; v, vagal ganglion.
All phenotypes assessed by phox2a expression at 36 hpf.
Number of embryos in each treatment group.
Significantly larger than contralateral control, see Fig. 4D.